Targeted-gene sequencing to catch triple negative breast cancer heterogeneity before and after neoadjuvant chemotherapy

HIGHLIGHTS

• who: Serena Di Cosimo and collaborators from the Department, University of Milan, Via Festa del Perdono, Milano, Italy have published the article: Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy, in the Journal: (JOURNAL) of 15/05/2019
• what: Premise, the goal of the study was to use a pragmatic approach with targeted-gene sequencing to analyze primary tumor somatic mutations and their changes in post-treatment samples of a homogenous cohort of TNBC patients. As known, the FDA has recently approved atezolizumab as an immunotherapy for TNBC . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.